SCYNEXIS (NASDAQ:SCYX) released its earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04, Fidelity Earnings reports. SCYNEXIS had a negative return on equity of 102.52% and a negative net margin of 8,592.97%. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million.
Shares of SCYNEXIS stock traded down $0.08 on Friday, reaching $1.50. 1,128,846 shares of the stock were exchanged, compared to its average volume of 1,395,365. SCYNEXIS has a one year low of $0.35 and a one year high of $2.15. The company has a current ratio of 4.53, a quick ratio of 4.53 and a debt-to-equity ratio of 0.27. The company has a market cap of $66.96 million, a PE ratio of -1.49 and a beta of 2.34.
Several brokerages have issued reports on SCYX. Zacks Investment Research downgraded shares of SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Tuesday. Brookline Capital Management reissued a “buy” rating on shares of SCYNEXIS in a research report on Friday, January 4th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. SCYNEXIS presently has a consensus rating of “Buy” and an average target price of $4.81.
TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2019/03/15/scynexis-scyx-posts-quarterly-earnings-results-beats-estimates-by-0-04-eps.html.
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Featured Story: How to calculate compound interest
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.